Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Non Operating Investment Income (2022 - 2025)

Corbus Pharmaceuticals Holdings has reported Non Operating Investment Income over the past 2 years, most recently at $6479.0 for Q4 2023.

  • For Q4 2023, Non Operating Investment Income fell 91.98% year-over-year to $6479.0; the TTM value through Dec 2023 reached $124536.0, up 295.67%, while the annual FY2023 figure was $124536.0, 295.67% up from the prior year.
  • Non Operating Investment Income for Q4 2023 was $6479.0 at Corbus Pharmaceuticals Holdings, down from $15753.0 in the prior quarter.
  • Over five years, Non Operating Investment Income peaked at $80782.0 in Q4 2022 and troughed at -$107248.0 in Q1 2022.